Announcement of share buyback program

August 19, 2026
Company announcement No. 14

The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be completed by the end of 2029. The program will be initiated and executed in accordance with authorizations granted by the Annual General Meeting.

The vast majority of shares acquired under the program will be cancelled, while a smaller portion will be retained to meet obligations arising from employee share-based incentive programs.

Novo Holdings, the company's principal shareholder, has informed Novonesis of its intention to participate in the share buyback program through sales of shares, thereby maintaining an ownership interest of approximately 25.5% of the company's share capital following the cancellation of shares repurchased under the program.

The share buyback program will be conducted in accordance with Article 5 of Regulation (EU) No. 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (the Safe Harbour Rules).

Contact information

Tobias Bjorklund
+45 3077 8682
tobb@novonesis.com

Anders Enevoldsen
+45 5350 1453
adev@novonesis.com

Louise Pugholm Aabo
lspa@novonesis.com

Publication of inside information pursuant to Market Abuse Regulation, Article 17.

About Novonesis
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group
Krogshoejvej 36
2880 Bagsvaerd
Denmark

CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38